Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase
Immunity · 2024
DOI: 10.1016/j.immuni.2024.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2024. Verfasst von Julia Lederhofer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Orthomyxoviridae Infections, Influenza, Human, Influenza Vaccines. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CCR NIH HHS, NCI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Continuously evolving influenza viruses cause seasonal epidemics and pose global pandemic threats. Although viral neuraminidase (NA) is an effective drug and vaccine target, our understanding of the NA antigenic landscape still remains incomplete. Here, we describe NA-specific human antibodies that target the underside of the NA globular head domain, inhibit viral propagation of a wide range of human H3N2, swine-origin variant H3N2, and H2N2 viruses, and confer both pre- and post-exposure protection against lethal H3N2 infection in mice. Cryo-EM structures of two such antibodies in complex with NA reveal non-overlapping epitopes covering the underside of the NA head. These sites are highly conserved among N2 NAs yet inaccessible unless the NA head tilts or dissociates. Our findings help guide the development of effective countermeasures against ever-changing influenza viruses by identifying hidden conserved sites of vulnerability on the NA underside.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: kanekiyom@nih.gov.
Förderung
- CCR NIH HHS
- NCI NIH HHS
- Intramural NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Lederhofer, J., Tsybovsky, Y., Nguyen, L., Raab, J. E., Creanga, A., Stephens, T., Gillespie, R. A., Syeda, H. Z., Fisher, B. E., Skertic, M., Yap, C., Schaub, A. J., Rawi, R., Kwong, P. D., Graham, B. S., McDermott, A. B., Andrews, S. F., King, N. P., & Kanekiyo, M. (2024). Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity. https://doi.org/10.1016/j.immuni.2024.02.003
Vancouver
Lederhofer J, Tsybovsky Y, Nguyen L, Raab JE, Creanga A, Stephens T, et al. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity. 2024. doi:10.1016/j.immuni.2024.02.003
BibTeX
@article{Lederhofer2024,
author = {Lederhofer, Julia and Tsybovsky, Yaroslav and Nguyen, Lam and Raab, Julie E and Creanga, Adrian and Stephens, Tyler and Gillespie, Rebecca A and Syeda, Hubza Z and Fisher, Brian E and Skertic, Michelle and Yap, Christina and Schaub, Andrew J and Rawi, Reda and Kwong, Peter D and Graham, Barney S and McDermott, Adrian B and Andrews, Sarah F and King, Neil P and Kanekiyo, Masaru},
title = {Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase},
journal = {Immunity},
year = {2024},
doi = {10.1016/j.immuni.2024.02.003}
}
EUVIMED